These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31145831)

  • 21. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.
    Kaplitt MG; Feigin A; Tang C; Fitzsimons HL; Mattis P; Lawlor PA; Bland RJ; Young D; Strybing K; Eidelberg D; During MJ
    Lancet; 2007 Jun; 369(9579):2097-105. PubMed ID: 17586305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GDNF delivery for Parkinson's disease.
    Patel NK; Gill SS
    Acta Neurochir Suppl; 2007; 97(Pt 2):135-54. PubMed ID: 17691299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease.
    Valles F; Fiandaca MS; Eberling JL; Starr PA; Larson PS; Christine CW; Forsayeth J; Richardson RM; Su X; Aminoff MJ; Bankiewicz KS
    Neurosurgery; 2010 Nov; 67(5):1377-85. PubMed ID: 20871425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer.
    Marks WJ; Baumann TL; Bartus RT
    Hum Gene Ther; 2016 Jul; 27(7):522-7. PubMed ID: 26711317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's Disease.
    Terse PS; Kells AP; Noker P; Wright JF; Bankiewicz KS
    Int J Toxicol; 2021; 40(1):4-14. PubMed ID: 33131343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.
    Kelly MJ; O'Keeffe GW; Sullivan AM
    Expert Rev Mol Med; 2015 May; 17():e8. PubMed ID: 25997719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
    Mandel RJ; Snyder RO; Leff SE
    Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation.
    Patel NK; Pavese N; Javed S; Hotton GR; Brooks DJ; Gill SS
    Neurology; 2013 Sep; 81(13):1176-8. PubMed ID: 23946313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
    Lang AE; Gill S; Patel NK; Lozano A; Nutt JG; Penn R; Brooks DJ; Hotton G; Moro E; Heywood P; Brodsky MA; Burchiel K; Kelly P; Dalvi A; Scott B; Stacy M; Turner D; Wooten VG; Elias WJ; Laws ER; Dhawan V; Stoessl AJ; Matcham J; Coffey RJ; Traub M
    Ann Neurol; 2006 Mar; 59(3):459-66. PubMed ID: 16429411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.
    Gasmi M; Herzog CD; Brandon EP; Cunningham JJ; Ramirez GA; Ketchum ET; Bartus RT
    Mol Ther; 2007 Jan; 15(1):62-8. PubMed ID: 17164776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands.
    Kirik D; Cederfjäll E; Halliday G; Petersén Å
    Neurobiol Dis; 2017 Jan; 97(Pt B):179-188. PubMed ID: 27616425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
    Marks WJ; Bartus RT; Siffert J; Davis CS; Lozano A; Boulis N; Vitek J; Stacy M; Turner D; Verhagen L; Bakay R; Watts R; Guthrie B; Jankovic J; Simpson R; Tagliati M; Alterman R; Stern M; Baltuch G; Starr PA; Larson PS; Ostrem JL; Nutt J; Kieburtz K; Kordower JH; Olanow CW
    Lancet Neurol; 2010 Dec; 9(12):1164-1172. PubMed ID: 20970382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
    Eslamboli A; Georgievska B; Ridley RM; Baker HF; Muzyczka N; Burger C; Mandel RJ; Annett L; Kirik D
    J Neurosci; 2005 Jan; 25(4):769-77. PubMed ID: 15673656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.
    Sanftner LM; Sommer JM; Suzuki BM; Smith PH; Vijay S; Vargas JA; Forsayeth JR; Cunningham J; Bankiewicz KS; Kao H; Bernal J; Pierce GF; Johnson KW
    Exp Neurol; 2005 Aug; 194(2):476-83. PubMed ID: 16022872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound.
    Xhima K; Nabbouh F; Hynynen K; Aubert I; Tandon A
    Mov Disord; 2018 Oct; 33(10):1567-1579. PubMed ID: 30264465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
    Yasuhara T; Shingo T; Date I
    Acta Med Okayama; 2007 Apr; 61(2):51-6. PubMed ID: 17471304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
    Bankiewicz KS; Eberling JL; Kohutnicka M; Jagust W; Pivirotto P; Bringas J; Cunningham J; Budinger TF; Harvey-White J
    Exp Neurol; 2000 Jul; 164(1):2-14. PubMed ID: 10877910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advances in the application of gene therapy for Parkinson's disease with adeno-associated virus].
    Chen Y; Lü YH; Li ZF
    Yao Xue Xue Bao; 2014 May; 49(5):576-81. PubMed ID: 25151724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys.
    Garbayo E; Ansorena E; Lana H; Carmona-Abellan MD; Marcilla I; Lanciego JL; Luquin MR; Blanco-Prieto MJ
    Biomaterials; 2016 Dec; 110():11-23. PubMed ID: 27697668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.